CIBC Asset Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.1M | Sell |
58,291
-11,456
| -16% | -$2.15M | 0.02% | 379 |
|
|
2026
Q1 | $13.8M | Sell |
69,747
-57,181
| -45% | -$11M | 0.03% | 316 |
|
|
2025
Q4 | $23.3M | Buy |
126,928
+4,566
| +4% | +$801K | 0.06% | 225 |
|
|
2025
Q3 | $18.8M | Buy |
122,362
+3,317
| +3% | +$502K | 0.05% | 219 |
|
|
2025
Q2 | $16.6M | Sell |
119,045
-778
| -0.6% | -$109K | 0.05% | 228 |
|
|
2025
Q1 | $17.6M | Buy |
119,823
+2,515
| +2% | +$364K | 0.06% | 212 |
|
|
2024
Q4 | $15.4M | Sell |
117,308
-1,826
| -2% | -$256K | 0.05% | 216 |
|
|
2024
Q3 | $18.6M | Buy |
119,134
+2,634
| +2% | +$425K | 0.06% | 193 |
|
|
2024
Q2 | $18.2M | Sell |
116,500
-351
| -0.3% | -$52.8K | 0.06% | 180 |
|
|
2024
Q1 | $15.8M | Buy |
116,851
+5,042
| +5% | +$668K | 0.05% | 207 |
|
|
2023
Q4 | $15.1M | Buy |
111,809
+5,946
| +6% | +$773K | 0.06% | 196 |
|
|
2023
Q3 | $14.3M | Buy |
105,863
+6,989
| +7% | +$955K | 0.06% | 189 |
|
|
2023
Q2 | $14.2M | Sell |
98,874
-517
| -0.5% | -$76.1K | 0.05% | 196 |
|
|
2023
Q1 | $13.8M | Buy |
99,391
+4,736
| +5% | +$637K | 0.05% | 198 |
|
|
2022
Q4 | $12.8M | Buy |
94,655
+13,427
| +17% | +$1.68M | 0.05% | 196 |
|
|
2022
Q3 | $8.91M | Buy |
81,228
+840
| +1% | +$107K | 0.04% | 243 |
|
|
2022
Q2 | $10.6M | Sell |
80,388
-2,163
| -3% | -$284K | 0.04% | 204 |
|
|
2022
Q1 | $11M | Buy |
82,551
+33,906
| +70% | +$4.07M | 0.04% | 226 |
|
|
2021
Q4 | $5.67M | Buy |
48,645
+1,681
| +4% | +$198K | 0.02% | 360 |
|
|
2021
Q3 | $5.64M | Buy |
46,964
+2,364
| +5% | +$275K | 0.02% | 326 |
|
|
2021
Q2 | $5.34M | Buy |
44,600
+3,547
| +9% | +$389K | 0.02% | 340 |
|
|
2021
Q1 | $4.08M | Buy |
41,053
+14,671
| +56% | +$1.47M | 0.02% | 365 |
|
|
2020
Q4 | $2.64M | Buy |
26,382
+9,822
| +59% | +$1.04M | 0.01% | 428 |
|
|
2020
Q3 | $1.81M | Buy |
+16,560
| New | +$1.84M | 0.01% | 467 |
|
|
2019
Q1 | – | Sell |
-14,688
| Closed | -$1.12M | – | 1110 |
|
|
2018
Q4 | $1.12M | Sell |
14,688
-6,432
| -30% | -$502K | 0.01% | 518 |
|
|
2018
Q3 | $1.67M | Sell |
21,120
-21,818
| -51% | -$1.65M | 0.01% | 470 |
|
|
2018
Q2 | $3.02M | Sell |
42,938
-11,535
| -21% | -$830K | 0.02% | 308 |
|
|
2018
Q1 | $3.81M | Sell |
54,473
-13,752
| -20% | -$953K | 0.02% | 258 |
|
|
2017
Q4 | $4.74M | Buy |
68,225
+1,555
| +2% | +$105K | 0.03% | 232 |
|
|
2017
Q3 | $4.52M | Buy |
66,670
+7,000
| +12% | +$442K | 0.03% | 236 |
|
|
2017
Q2 | $4.07M | Buy |
59,670
+8,515
| +17% | +$556K | 0.03% | 246 |
|
|
2017
Q1 | $3.19M | Buy |
51,155
+25,015
| +96% | +$1.46M | 0.02% | 293 |
|
|
2016
Q4 | $1.43M | Sell |
26,140
-4,135
| -14% | -$235K | 0.01% | 467 |
|
|
2016
Q3 | $1.99M | Buy |
+30,275
| New | +$1.98M | 0.01% | 379 |
|
|
2014
Q2 | – | Sell |
-64,200
| Closed | -$4.17M | – | 809 |
|
|
2014
Q1 | $4.17M | Sell |
64,200
-28,420
| -31% | -$1.84M | 0.02% | 250 |
|
|
2013
Q4 | $5.5M | Sell |
92,620
-5,682
| -6% | -$309K | 0.03% | 203 |
|
|
2013
Q3 | $5.11M | Sell |
98,302
-99,984
| -50% | -$5.02M | 0.03% | 205 |
|
|
2013
Q2 | $9.38M | Buy |
+198,286
| New | +$10.1M | 0.06% | 122 |
|
Other funds holding AZN
EP
IA
CIBC Asset Management's AZN Position: Q2 2026 in Review
CIBC Asset Management reduced its AstraZeneca (AZN) stake by 16% in Q2 2026, selling an estimated $2.15M and leaving 58,291 shares worth $11.1M. The position accounts for 0.02% of the portfolio, ranked #379.
CIBC Asset Management first reported a position in AZN in Q2 2013 and has held it in 38 quarters since. The position peaked at $23.3M in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- CIBC Asset Management held 58,291 shares of AstraZeneca worth $11.1M as of Q2 2026.
- CIBC Asset Management sold 11,456 AstraZeneca shares in Q2 2026, an estimated $2.15M.
- AstraZeneca made up 0.02% of CIBC Asset Management's portfolio in Q2 2026, its #379 holding.
- CIBC Asset Management first reported a position in AstraZeneca in Q2 2013 and has held it in 38 quarters since.
- CIBC Asset Management's AstraZeneca position peaked at $23.3M in Q4 2025.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.